9-Valent and 4-Valent HPV Vaccine Effectiveness and Herd Protection among Young Women, 11 Years after Vaccine Introduction
Purpose: A 9-valent HPV vaccine that prevents HPV6, 11, 16, 18, 31, 33, 45, 52, and 58 was introduced in 2015. Clinical trials have demonstrated that the 9-valent as well as the 2-valent (HPV16, 18) and 4-valent (HPV6, 11, 16, 18) vaccines have high efficacy in preventing vaccine-targeted HPV types and associated pre-cancers, but surveillance studies are needed to examine the impact of vaccine introduction in community settings. The aims of this study were: 1) to assess vaccine effectiveness by determining the prevalence of 4- and 9-valent vaccine-type HPV in vaccinated young women, and 2) to assess herd protection by determining the prevalence of 4- and 9-valent vaccine-type HPV in unvaccinated young women, before and during the 11 years after HPV vaccines introduction in a community.
Source: Journal of Adolescent Health - Category: Child Development Authors: Chelse Spinner, Lili Ding, David Bernstein, Darron R. Brown, Eduardo L. Franco, Jessica A. Kahn Source Type: research
More News: Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer Vaccines | Clinical Trials | Study | Vaccines | Women